Table 2

FMO3 genotypes in FAP patients who underwent primary chemoprevention trial

PolymorphismsTotal n = 41Sulindac group n = 21Placebo group n = 20
P153L
WT/WT39 (95)19 (90)20 (100)
WT/P2 (5)2 (10)0
P/P000
E158K
WT/WT16 (39)7 (33)9 (45)
WT/P17 (41)10 (48)7 (35)
P/P8 (20)4 (19)4 (20)
V257M
WT/WT36 (88)19 (90)17 (85)
WT/P5 (12)2 (10)3 (15)
P/P000
E305X
WT/WT28 (68)14 (67)14 (70)
WT/P13 (32)7 (33)6 (30)
P/P000
E308G
WT/WT13 (32)2 (10)11 (55)
WT/P22 (54)17 (80)5 (25)
P/P6 (14)2 (10)4 (20)
  • NOTE. Values are expressed as number (%).